More efforts need to be made to remove unconscious bias when implementing approved diabetes technologies into clinical practice for all patients, said Viral Shah, MD, an endocrinologist and scientist.
Uptake in diabetes technology is lower among people in more diverse populations because of several factors, including a lack of representation in clinical trials and unconscious bias, according to Viral Shah, MD, endocrinologist and associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, Adult Clinic School of Medicine at the University of Colorado Anschutz campus.
Transcript
What are some changes that need to take place to achieve better health equity and reduce disparities in the uptake of diabetes technologies?
I think there are a number of publications that suggest that, unfortunately, the diabetes technology uptake has been low amongst the minority compared to the Whites in type 1 [diabetes] studies, and type 2s as well, suggest the same thing.
There are multiple reasons for that, I think, and we need to address all these multiple facets to reduce that kind of health care disparity in caring for patients with diabetes. And one of the aspects, and we published that in Diabetes Care last year, is that if you look at all this randomized controlled trial that forms the evidence to use these technologies in managing type 1 or type 2 diabetes, more than 70% of the participants in those clinical trials are Whites. And so unfortunately, when we are not recruiting minorities in a clinical trial, we don't know much about that how this technology is going to work in minorities. For example, the Spanish speaking people might need a screen that is in Spanish. They might have some kind of a different requirement to use that technology. So unless we study that, we don't know. And technology is not just about the science, but it's also about the human factor: how the patients are going to use that part, right? So I think I would suggest that companies should try to probably put some more resources in recruiting minorities in a clinical trial, so that we can understand how these things can work for them.
The second part of that is that once those technologies are available, approved, then how to implement that in a clinical practice so that we can use that for our patients—regardless of their skin color, regardless of their education level, regardless of the language that they speak. I think it will require a lot of efforts because I think there are some unconscious bias among physicians—among all of us. Unfortunately, we need to do more to remove that unconscious bias. There are multiple factors responsible for this gap, and if we can address those factors, I'm sure that we can reduce the disparity. But the first step is that you are asking the question; I feel like it's a first step that hey, we need to be aware about that. Once we are aware, then we'll think about closing the gap.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Top Pharmacy Leaders to Convene at Asembia’s AXS25 Summit in Las Vegas
April 24th 2025Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Top Pharmacy Leaders to Convene at Asembia’s AXS25 Summit in Las Vegas
April 24th 2025Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.
Read More
2 Commerce Drive
Cranbury, NJ 08512